Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514833 | 0.86 | GPR35 (0.58) | GPR35SMN1; SMN2TDP1ALDH1A1TSHR | |
| SCHEMBL3393735 | 0.86 | GPR35 (0.46) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL6737148 | 0.85 | SMN1; SMN2 (0.46) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| Alcohol SCHEMBL11148831 | 0.84 | FBP1 (0.46) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL3599344 | 0.83 | SMN1; SMN2 (0.47) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL6741088 | 0.83 | SMN1; SMN2 (0.47) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL11032366 | 0.81 | TSHR (0.52) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL1668133 | 0.81 | TDP1 (0.48) | GPR35SMN1; SMN2PDE7ATDP1ALDH1A1 | |
| SCHEMBL8399481 | 0.79 | GPR35 (0.58) | GPR35SMN1; SMN2TDP1ALDH1A1TSHR | |
| SCHEMBL5622028 | 0.79 | ALDH1A1 (0.53) | GPR35SMN1; SMN2TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2592083-A1 | FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd. (CN) | 2013-05-15 | — | — | EP | disclosed |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2011-11-24 | — | — | US | disclosed |
| US-8044047-B2 | 5-substituted benzoxazines | HOFFMAN-LA ROCHE INC. (US) | 2011-10-25 | — | — | US | disclosed |
| CN-102149698-A | 5-substituted benzoxazines | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | disclosed |
| EP-2328881-A1 | 5-SUBSTITUTED BENZOXAZINES | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20100063042-A1 | 5-SUBSTITUTED BENZOXAZINES | HOFFMANN-LA ROCHE, INC. | 2010-03-11 | — | — | US | disclosed |
| WO-2010026112-A1 | 5-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| CN-101489989-A | Pentadiene amide derivative | KYOWA HAKKO KIRIN CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | GPR35 3216/4885SMN1; SMN2 4672/4885PDE7A 2536/4885 |
| US-20110288086-A1 | POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF | AURKA, AURKC, AURKB | GPR35 2396/4885SMN1; SMN2 4624/4885PDE7A 876/4885 |
| US-20100063042-A1 | 5-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | GPR35 26/4885SMN1; SMN2 1235/4885PDE7A 634/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | GPR35 2630/4885SMN1; SMN2 3258/4885PDE7A 1385/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | GPR35 2694/4885SMN1; SMN2 4556/4885PDE7A 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.